Dr Dietmar Berger is announced as Gilead Sciences new Chief Medical Officer. He will succeed Dr Merdad Parsey at the start of 2025. Berger, a board-certified internist, haematologist and oncologist, ...

Gilead Sciences announced the departure of chief medical officer Merdad Parsey, MD, PhD. The company appointed Dietmar Berger as his successor and Parsey will retain his role until Q1 2025. He joined ...

Elsewhere, Gilead CEO Daniel O’Day hired Berger away from Sanofi. Synaffix B.V., a Lonza company (SIX: LONN) focused on commercializing its clinical-stage platform technology for the development ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Former Liverpool Member of Parliament Luciana Berger has been made a peer in the House of Lords. Ms Berger represented the Liverpool Wavertree constituency as an MP between 2010 and 2019.

December 12, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Dietmar Berger, MD, PhD, will join the company on January 2, 2025, as Chief Medical Officer and will become a member of ...

Gilead Sciences (GILD) closed the most recent trading day at $91.09, moving +0.44% from the previous trading session. The stock's change was more than the S&P 500's daily loss of 0.09%. Elsewhere ...

Julius Berger Nigeria PLC has blamed contractual differences for the delay in the completion of the Bodo-Bonny Road project that was awarded in 2014. The company said it remained committed to the ...

Gilead's stock has surged due to successful launches of Livdelzi for PBC and promising developments in lenacapavir for HIV prevention. Livdelzi's approval and strong market potential, combined ...

Viridian shares soar after latest trial success for thyroid eye disease drug December 16, 2024 Gilead Sciences said on Thursday it has appointed Sanofi's Dietmar Berger as its chief medical ...

Gilead (GILD) and Terray Therapeutics announced that the companies have entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets.